Table II.
Association between serum MMP-9 and VEGF levels with clinicopathological characteristics of IDC patients.
| Characteristics | Cases (n) | VEGF (pg/ml) | P-value | MMP-9 (ng/ml) | P-value |
|---|---|---|---|---|---|
| Tumor size (cm) | <0.001 | <0.001 | |||
| <2 | 133 | 96.55 (1-345) | 524.71 (63-2553) | ||
| <5≥2 | 114 | 158.61 (<0.025-1044) | 1051.40 (101-5112) | ||
| ≥5 | 54 | 278.89 (13-926) | 1756.00 (392-4786) | ||
| Clinical stage (UICC 7th) | <0.001 | <0.001 | |||
| I | 125 | 86.12 (0-488) | 413.05 (63-833) | ||
| II | 58 | 106.14 (10-281) | 682.33 (125-1377) | ||
| III | 98 | 207.2 (13-1044) | 1435.35 (533-3041) | ||
| IV | 20 | 295.55 (52-926) | 2630.05 (1035-5112) | ||
| Lymph node metastasis | 0.001 | <0.001 | |||
| Negative | 166 | 93.62 (0-1044) | 475.77 (63-1377) | ||
| Positive | 127 | 231.07 (13-926) | 1566.80 (445-5112) | ||
| Missing | 8 | 136.88 (1-319) | 813.88 (238-2337) | ||
| Age (years) | 0.53 | 0.104 | |||
| <35 | 21 | 122.38 (10-345) | 783.38 (125-2553) | ||
| <50≥35 | 116 | 154.22 (13-756) | 1006.11 (82-4786) | ||
| ≥50 | 164 | 155.62 (0-1044) | 922.63 (63-5112) |
MMP-9, matrix metalloproteinase-9; VEGF, vascular endothelial growth factor; IDC, infiltrative ductal carcinoma; UICC, Union for International Cancer Control.